地缘风险催化下，生命科学上游(细胞培养基、生物试剂、层析介质等)国产替代需求迫切，目前细分领 域国内市占率低，各企业有望凭借新分子品类或高性价比产品抢占市占率。叠加国内与海外新靶点新机 理研发需求提升，带动细分赛道(如药效、抗体、蛋白质等)需求增长，行业长期成长逻辑清晰，短期业 绩边际改善显著。 广发证券主要观点如下： 国内投融资研发需求修复，叠加行业订单价格企稳CRO企业底部向上趋势明确 国内研发需求端边际改善，创新药出海BD带动研发积极性回升，国内研发订单需求增长，行业价格自 2023年降价后已见底企稳，部分领域略有回升。临床CRO(泰格医药（300347）、诺思格（301333）、 普蕊斯（301257）)2025年营收增速已逐步转正，临床前CRO业绩亦持续改善;扣非归母净利润环比修复 显著;国内CRO临床数据认可度提升，泰格医药海外业务贡献总量显著。预计2026年整个板块将迎来更 好的业绩增长。 CDMO新签订单延续季度改善趋势，行业新分子为行业发展带来新增量 2025年CDMO业绩已触底回升，全球创新药研发需求复苏带动行业新签订单与在手订单整体保持增长， 新分子赛道需求打开增量空间;同时，前期产能建 ...

Core Viewpoint - The domestic R&D demand is showing marginal improvement, driven by the overseas expansion of innovative drugs, leading to a recovery in R&D orders and stabilization of industry prices after a decline in 2023. The CRO sector is expected to see better performance growth by 2026, while the CDMO industry has also reached a bottom and is poised for continued strong growth due to robust demand for new molecules and new orders [1][2][3]. CRO Sector - The domestic R&D demand is recovering, with an increase in orders and stabilization of prices, indicating a clear upward trend for CRO companies. Clinical CROs like Tigermed, Nossan, and Prasis are expected to see revenue growth turning positive by 2025, with significant contributions from overseas business [2][3]. - The recognition of domestic CRO clinical data is improving, which is beneficial for companies like Tigermed [2]. CDMO Sector - The CDMO sector has seen a recovery in performance, with new orders continuing to improve quarterly. The global demand for innovative drug R&D is driving growth in new orders and backlog [3]. - The industry is benefiting from increased capacity utilization and profitability, with a strong certainty of performance and profit growth expected to continue into 2026 [3]. Life Sciences Sector - The life sciences upstream sector is experiencing a dual drive from domestic substitution and overseas expansion, with urgent demand for domestic alternatives in areas like cell culture media and biological reagents. Companies are expected to capture market share through new product categories and cost-effective offerings [4]. - The demand for specific segments such as drug efficacy, antibodies, and proteins is increasing, indicating a clear long-term growth logic for the industry [4]. API Sector - The raw material pharmaceutical industry is currently in a phase of price bottoming and supply surplus, with traditional product performance under pressure. However, companies are extending their business into generics, innovative drugs, and specialty APIs, which may lead to value reconstruction through business structure optimization [5]. - The valuation of raw material pharmaceutical companies is at a low point, presenting opportunities based on changes in new business layouts [5]. Investment Recommendations - For clinical and preclinical CROs, companies like Tigermed, Nossan, and Yinos are recommended due to the gradual recovery of the industry and expected improvement in order structure [6]. - In the CDMO sector, companies such as WuXi AppTec, WuXi Biologics, and others with strong fundamentals and capacity advantages are highlighted for their potential benefits from industry recovery and high demand for new molecules [6]. - In the life sciences upstream sector, companies like Baitai Biotechnology and others are recommended due to accelerated domestic substitution and strong overseas growth [6]. - Companies like Pro Pharma and Huahai Pharmaceutical are noted for their new business layouts that are expected to contribute significant value increments [6].

Core Viewpoint - GLP-1 related business is a significant growth driver for the company's life sciences segment, with a focus on market share and collaboration with major clients [1] Group 1: Market Position and Revenue - The company maintains a market share of over 70% for GLP-1 peptide solid-phase synthesis carriers in the domestic clinical pipeline [1] - In the first half of 2025, the company's revenue from the life sciences sector reached 320 million yuan [1] Group 2: Product Range and Client Base - The company offers a diverse range of products in the life sciences field, including solid-phase synthesis carriers for peptides, small nucleic acid synthesis carriers, chromatography fillers, chromatography media, and enzyme carriers [1] - The main downstream customers for the company's peptide solid-phase synthesis carriers are CDMO enterprises, although specific sales revenue and client information for each product type have not been disclosed [1] Group 3: Collaboration with Major Clients - The company is in collaboration with leading clients such as Eli Lilly and Novo Nordisk, focusing on long-term supply agreements and product delivery schedules [1]

Core Insights - 蓝晓科技 reported a revenue of 1.933 billion yuan for the first three quarters of 2025, a year-on-year increase of 2.2%, and a net profit attributable to shareholders of 652 million yuan, up 9.3% year-on-year [1] - In Q3 2025, the company achieved a revenue of 686 million yuan, marking a 14.9% year-on-year increase and a 2.3% quarter-on-quarter increase, with a net profit of 207 million yuan, up 7.7% year-on-year but down 17.6% quarter-on-quarter [1] - The gross profit margin for the first three quarters of 2025 was 52.81%, with Q3 gross profit margin reaching a record high of 55.6%, driven by an increase in high-margin businesses such as life sciences and metal resources [1] Financial Performance - The sales net profit margin for Q3 2025 was 30.42%, showing a decline both year-on-year and quarter-on-quarter due to increased expense ratios and higher income tax [2] - The expense ratio in Q3 was 14.3%, with financial expenses incurred, contrasting with the previous three quarters where financial income was recorded [2] - Income tax for Q3 2025 was 62 million yuan, an increase of 31 million yuan year-on-year and 44 million yuan quarter-on-quarter, significantly impacting net profit [2] Strategic Developments - 蓝晓科技 is constructing a high-end materials industrial park for life sciences, planning to purchase 270 acres of land in Pucheng High-tech Development Zone [3] - The company has established a subsidiary in Sweden and a European regional headquarters for life sciences, appointing industry expert Hans Johansson as the general manager to oversee operations and strategic development in the region [3] - This strategic move reflects the company's commitment to deepening its presence in the European market and aligning with global cutting-edge technologies [3] Profit Forecast - The profit forecast for 蓝晓科技 remains at 1.011 billion yuan, 1.322 billion yuan, and 1.596 billion yuan for 2025, 2026, and 2027 respectively, maintaining a "buy" rating [4]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6]. Core Insights - The company achieved a record high single-quarter gross margin of 55.6% in Q3 2025, driven by an increase in high-margin businesses such as life sciences and metal resources [2][4]. - For the first three quarters of 2025, the company reported a revenue of 1.933 billion yuan, a year-on-year increase of 2.2%, and a net profit attributable to the parent company of 652 million yuan, up 9.3% year-on-year [1][2]. - The third quarter of 2025 saw a revenue of 686 million yuan, marking a 14.9% year-on-year increase and a 2.3% quarter-on-quarter increase [1][2]. Financial Performance - The gross margin for the first three quarters of 2025 was 52.81%, with the third quarter achieving a gross margin of 55.6%, the highest since the company's listing [2]. - The net profit margin for Q3 2025 was 30.42%, showing a decline due to increased expense ratios and higher income tax [3]. - The company plans to invest in a high-end materials industrial park for life sciences, purchasing 270 acres of land in Pucheng High-tech Zone [4]. Future Outlook - The company has set profit forecasts for 2025-2027 at 1.011 billion yuan, 1.322 billion yuan, and 1.596 billion yuan respectively, indicating a positive growth trajectory [4]. - The establishment of a subsidiary in Sweden aims to strengthen the company's presence in the European life sciences market [4].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company's profitability quality continues to improve, with a historical high sales gross margin of 52.81% achieved in the first three quarters of 2025 [4] - The life sciences segment shows promising growth, with significant investments in high-end materials and breakthroughs in lithium extraction and water treatment [5] - The company reported a revenue of 1.933 billion yuan in Q3 2025, a year-on-year increase of 2.20%, and a net profit attributable to shareholders of 652 million yuan, up 9.27% year-on-year [4] Financial Performance Summary - For the first three quarters of 2025, the company achieved a revenue of 1.933 billion yuan, with a net profit of 652 million yuan and a basic earnings per share of 1.28 yuan [3][4] - The revenue from the adsorption separation materials business reached 1.565 billion yuan, accounting for 80.95% of total revenue, while the system device business contributed 248 million yuan, representing 12.83% [4] - The company expects net profits of 919 million yuan, 1.085 billion yuan, and 1.262 billion yuan for 2025, 2026, and 2027, respectively, with corresponding PE ratios of 30x, 26x, and 22x [5][6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported steady growth in its core business for Q3, with a significant acceleration in the life sciences segment [5][6] - For Q3 2025, the company achieved operating revenue of 6.86 billion yuan, a year-on-year increase of 14.86% and a quarter-on-quarter increase of 2.29% [5] - The net profit attributable to the parent company for Q3 was 2.07 billion yuan, reflecting a year-on-year increase of 7.72% but a quarter-on-quarter decline of 17.58% due to increased income tax expenses [6] Summary by Sections Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of 19.33 billion yuan, a year-on-year increase of 2.20%, and a net profit of 6.52 billion yuan, up 9.27% year-on-year [5] - The gross profit margin for Q3 2025 was 52.81%, an increase of 4 percentage points year-on-year, driven by higher contributions from high-margin businesses [5] Business Segments - The adsorption materials segment showed robust growth, with revenue from adsorption separation materials reaching 15.65 billion yuan, a year-on-year increase of 7.19% [5] - The life sciences business is expected to continue its strong growth trajectory, particularly in the peptide solid-phase synthesis carrier business, with several key GLP-1 peptide projects progressing well [5][8] Future Outlook - The company plans to invest 1.15 billion yuan in a high-end materials industrial park for life sciences, which is expected to enhance production capacity and support future growth [8] - Projections for net profit from 2025 to 2027 are 9.69 billion yuan, 11.89 billion yuan, and 14.49 billion yuan, respectively, with corresponding P/E ratios of 29, 24, and 19 [9]

Core Insights - The company achieved a record high gross margin of 55.62% in Q3 2025, driven by an increase in high-margin businesses such as life sciences and metal resources, alongside a decrease in the price of core raw material styrene by 22.51% year-on-year and 4.93% quarter-on-quarter [1] - The company plans to build a high-end materials industrial park for life sciences in Pucheng, Shaanxi, focusing on high-value-added products, which is expected to enhance the long-term return on equity (ROE) [2] - The establishment of a subsidiary in Sweden and a European regional headquarters for life sciences is aimed at attracting top global talent and enhancing the company's technological and customer resource accumulation in the life sciences sector [3] - Revenue forecasts for 2025-2027 are projected at 2.74 billion, 3.298 billion, and 4.018 billion yuan, with year-on-year growth rates of 7.28%, 20.35%, and 21.84% respectively, indicating a strong growth trajectory [4] Financial Performance - In Q3 2025, the company reported a gross margin of 55.62%, an increase of 4.42 percentage points quarter-on-quarter, although the net profit margin decreased by 1.84 percentage points due to rising expense ratios [1] - The company’s revenue for the first three quarters of 2025, excluding the impact of lithium project income, grew by 8% year-on-year, with continued growth in life sciences, metal resources, water treatment, and ultra-pure water businesses [1] Strategic Developments - The company is focusing capital expenditures on high-value-added life sciences businesses, with a strategic shift from industrial products to life sciences products, which is expected to improve the revenue structure and ROE levels [2] - The appointment of Hans Johansson as the general manager of the new Swedish subsidiary is expected to leverage his extensive experience in chromatography and bioprocessing to enhance the company's capabilities in life sciences [3]

Investment Rating - The report maintains a "Buy-B" rating for the company [1] Core Views - The company has shown steady revenue growth and is heavily investing in the life sciences sector, which is expected to benefit from the industrialization of Direct Air Capture (DAC) technology [1][3] - The company's revenue for the first half of 2025 was 1.247 billion yuan, a decrease of 3.64% year-on-year, while the total profit reached 501 million yuan, an increase of 12.35% year-on-year [1] - The gross profit margin improved to 51.26%, up 3.8 percentage points year-on-year, driven by a higher proportion of high-margin products and a decline in raw material prices [2] Financial Performance - The company is projected to achieve revenues of 3.094 billion yuan, 3.844 billion yuan, and 4.703 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 21.15%, 24.24%, and 22.36% [4] - The net profit attributable to the parent company is expected to be 1.011 billion yuan, 1.254 billion yuan, and 1.560 billion yuan for the years 2025, 2026, and 2027, reflecting year-on-year growth rates of 28.40%, 24.05%, and 24.39% [4] - The company’s earnings per share (EPS) are projected to be 1.99 yuan, 2.47 yuan, and 3.07 yuan for the years 2025, 2026, and 2027, with corresponding price-to-earnings (P/E) ratios of 27.62, 22.27, and 17.90 [4] Market Data - As of September 4, 2025, the closing price of the company's stock was 53.48 yuan, with a market capitalization of 27.15 billion yuan [7] - The company’s circulating A-shares account for 3.07 billion out of a total of 5.08 billion shares [7] Strategic Initiatives - The company plans to invest 1.15 billion yuan in a high-end materials industrial park focused on life sciences, which will include various chromatography media and separation materials [2] - The company is expected to benefit from the DAC market, projected to grow from 62 million USD in 2023 to 1.727 billion USD by 2030, with a compound annual growth rate (CAGR) of 60.9% [3]

Core Insights - The company reported its H1 2025 financial results, with revenue, net profit attributable to shareholders, and net profit excluding non-recurring items at 1.25 billion, 450 million, and 440 million yuan respectively, showing a year-on-year change of -3.6%, +10%, and +11.1% [1] - In Q2 2025, the company achieved revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 670 million, 250 million, and 250 million yuan respectively, with year-on-year changes of +1%, +7%, and +8.1%, and quarter-on-quarter changes of +16.3%, +30.2%, and +29.1% [1] - The revenue growth in Q2 was primarily impacted by maintenance activities, while structural optimization contributed to improved profitability [1] Financial Performance - H1 2025 basic warehouse business revenue increased by 4.3% year-on-year, demonstrating resilience [1] - Revenue growth in specific sectors for H1 2025 included metals (+22.8%), life sciences (+12.4%), water (+11.3%), while sectors like environmental protection (-43.2%), food (+30.6%), and chemicals (-29.7%) showed varied performance [1] - The gross margin and net margin for H1 2025 increased by 3.8 and 4.3 percentage points year-on-year, respectively, driven by a higher revenue share from high-margin segments [1] Strategic Developments - The company plans to invest 1.15 billion yuan in a high-end materials industrial park for life sciences in Pucheng, Shaanxi, expanding its capital expenditure in high-ROE sectors [2] - The product range will include chromatography media, polymer chromatography fillers, enzyme carriers, and ultra-pure water-grade adsorption separation materials, marking a deeper strategic shift from industrial to pharmaceutical sectors [2] - Key focus areas for the second half of the year include lithium and life sciences, with significant developments expected in lithium business projects and commercialization of chromatography media [2] Earnings Forecast and Investment Recommendations - The company is projected to achieve revenues of 3.085 billion, 3.824 billion, and 4.679 billion yuan for 2025-2027, with year-on-year growth rates of 20.78%, 23.98%, and 22.34% respectively [3] - Net profit attributable to shareholders is expected to reach 959 million, 1.204 billion, and 1.548 billion yuan for the same period, with growth rates of 21.85%, 25.55%, and 28.53% respectively [3] - The current stock price corresponds to P/E ratios of 28.29, 22.54, and 17.53 for 2025-2027, indicating potential for valuation re-rating as the company transitions towards higher value-added pharmaceutical sectors [3]